(Bloomberg) -- UnitedHealth Group Inc.’s Oxford unit, which runshealth plans in the northeastern U.S., will favor Sanofi and Regeneron Pharmaceuticals Inc.’s newcholesterol-cutting shot over a similar treatment madeby Amgen Inc.

Oxford covers about 1.2 million people, according to datacompiled by Bloomberg.

Its patients will have to take Sanofi and Regeneron’s injectionPraluent for 12 weeks without sufficient effect or have a historyof not being able to tolerate the drug before the insurer willcover Amgen’s drug Repatha, the company said in an update postedonline. The policy takes effect on Jan. 1.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.